Drugs that contain Dexlansoprazole
1. Dexilant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
| US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(3 years ago) | |
| US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(1 year, 2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
|
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(3 years ago) | |
|
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
|
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(8 months ago) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months ago) | |
| US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months ago) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(4 days ago) | |
|
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(4 days ago) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 10 months from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(2 years from now) | |
| US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(2 years from now) | |
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(2 years from now) | |
|
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(2 years from now) | |
|
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(2 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
| US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(5 years from now) | |
|
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(6 years from now) | |
| US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
Market Authorisation Date: 30 January, 2009
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
2. Dexilant Solutab patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
| US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
| US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(3 years ago) | |
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(1 year, 2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7399485 | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
May, 2018
(5 years ago) | |
|
US7399485 (Pediatric) | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
Nov, 2018
(5 years ago) | |
| US6238994 | TAKEDA PHARMS USA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May, 2019
(4 years ago) | |
| US6328994 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
| US7431942 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
| US7875292 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
|
US6238994 (Pediatric) | TAKEDA PHARMS USA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov, 2019
(4 years ago) | |
|
US7431942 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
|
US6328994 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
|
US7875292 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
| US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
|
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
|
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(3 years ago) | |
|
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(8 months ago) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months ago) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(4 days ago) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 10 months from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(2 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
|
US8871273 (Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(4 years from now) | |
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(4 years from now) | |
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB family patents